Targeting lipid metabolism in metastatic prostate cancer

Tahlia Scheinberg, Blossom Mak, Lisa Butler, Luke Selth, Lisa G. Horvath

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)
174 Downloads (Pure)


Despite key advances in the treatment of prostate cancer (PCa), a proportion of men have de novo resistance, and all will develop resistance to current therapeutics over time. Aberrant lipid metabolism has long been associated with prostate carcinogenesis and progression, but more recently there has been an explosion of preclinical and clinical data which is informing new clinical trials. This review explores the epidemiological links between obesity and metabolic syndrome and PCa, the evidence for altered circulating lipids in PCa and their potential role as biomarkers, as well as novel therapeutic strategies for targeting lipids in men with PCa, including therapies widely used in cardiovascular disease such as statins, metformin and lifestyle modification, as well as novel targeted agents such as sphingosine kinase inhibitors, DES1 inhibitors and agents targeting FASN and beta oxidation.

Original languageEnglish
Pages (from-to)1-30
Number of pages30
JournalTherapeutic Advances in Medical Oncology
Publication statusPublished - 30 Jan 2023


  • high-fat diet
  • lipids
  • prostate cancer
  • targeted therapy


Dive into the research topics of 'Targeting lipid metabolism in metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this